Stryker Corp. (SYK-N) Stock Predictions - Stockchase
WATCH LIST
56
Stryker Corp. (SYK-N)

ON STOCKCHASE SINCE Feb 2002

manufactures orthopedic equipment

biotechnology/pharmaceutical

Stryker Corp. Stryker Corp.
SYK-N

20 56
biotechnology/pharmaceutical

Stryker Corp. (SYK-N) SAVE

168.94

4.16 (2.4%)

Oct, 20, 2018, 12:00 am

OPINIONS

About Stryker Corp. (SYK-N)

Stryker Corporation is a Fortune 500 medical technologies firm based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and ... More at Wikipedia

What the experts are saying about SYK-N



  • All
  • Filtered
Signal Opinion Expert
PAST TOP PICK
Stryker Corp.(SYK-N) 

October 12, 2018

(A Top Pick August 21/17, Up 20%) Hips and knees. Robotic surgery and 3D printers. His fear is that Stryker will buy Globus, and the subsidiary will overtake the parent.

biotechnology/pharmaceutical

(A Top Pick August 21/17, Up 20%) Hips and knees. Robotic surgery and 3D printers. His fear is that Stryker will buy Globus, and the subsidiary will overtake the parent.

biotechnology/pharmaceutical
David Driscoll

President , Liberty Internationa...

Price Price
$171.040
Owned Owned
Yes

HOLD
Stryker Corp.(SYK-N) 

September 12, 2018

This is a great company, he says, with a well-established track record.  The price is getting to the point, where you are paying a premium at this level.  He would diversify into other holdings as well, ideally through an ETF such as IHI-N  

biotechnology/pharmaceutical

This is a great company, he says, with a well-established track record.  The price is getting to the point, where you are paying a premium at this level.  He would diversify into other holdings as well, ideally through an ETF such as IHI-N  

biotechnology/pharmaceutical
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$173.290
Owned Owned
No

COMMENT
Stryker Corp.(SYK-N) 

August 7, 2018

They make bespoke equipment. This can never be Amazon’d because the representative from Stryker works so closely with the doctor when they implant a new device into a patient. They are well-run, their robotics are leading edge. He likes the sector and this individual company but he would manage the idiosyncratic risk in this space by buying the IHI (US medical devices) ETF.

biotechnology/pharmaceutical

They make bespoke equipment. This can never be Amazon’d because the representative from Stryker works so closely with the doctor when they implant a new device into a patient. They are well-run, their robotics are leading edge. He likes the sector and this individual company but he would manage the idiosyncratic risk in this space by buying the IHI (US medical devices) ETF.

biotechnology/pharmaceutical
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$165.180
Owned Owned
No

TOP PICK
Stryker Corp.(SYK-N) 

August 7, 2018

Compared to the competition, Stryker has 8% organic growth due to hips and knees business. Robotics for knees and 3D printers for hips are giving them an edge. Dividend’s been rising 14-15% per year. The premier medical device company. Yield is 1.1%. (Analysts’ price target is $182.10)

biotechnology/pharmaceutical

Compared to the competition, Stryker has 8% organic growth due to hips and knees business. Robotics for knees and 3D printers for hips are giving them an edge. Dividend’s been rising 14-15% per year. The premier medical device company. Yield is 1.1%. (Analysts’ price target is $182.10)

biotechnology/pharmaceutical
David Driscoll

President , Liberty Internationa...

Price Price
$165.180
Owned Owned
Yes

BUY
Stryker Corp.(SYK-N) 

July 5, 2018

They are growing on robotics. On knee and hip are going to be the dominant player. It is the new wave.

biotechnology/pharmaceutical

They are growing on robotics. On knee and hip are going to be the dominant player. It is the new wave.

biotechnology/pharmaceutical
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$171.330
Owned Owned
Yes

BUY
Stryker Corp.(SYK-N) 

June 20, 2018

He has been watching them since $100.  They benefit from an economic barrier to entry, because competitors will struggle to gain market share due to the complexity of the medical procedures used to implant the devices.  There is a rumour they may look to make a major acquisition.  For a 5-10 year horizon, this is a great core holding.  Yield %.  (Analysts’ price target is unkown)

biotechnology/pharmaceutical

He has been watching them since $100.  They benefit from an economic barrier to entry, because competitors will struggle to gain market share due to the complexity of the medical procedures used to implant the devices.  There is a rumour they may look to make a major acquisition.  For a 5-10 year horizon, this is a great core holding.  Yield %.  (Analysts’ price target is unkown)

biotechnology/pharmaceutical
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$169.540
Owned Owned
No

BUY
Stryker Corp.(SYK-N) 

June 12, 2018

This is a terrific company and demographics for their artificial hips and knees are very positive. They are rumoured to be considering buying Boston Scientific. Because of the high rumoured price, Boston Scientific is up today, and Stryker is down. He thinks that this area is very investible because long-term growth is so good. People should have an investment in this area. The 10% drop in the stock price yesterday piqued his interest, at this price. Price at time of interview was $164.15.

biotechnology/pharmaceutical

This is a terrific company and demographics for their artificial hips and knees are very positive. They are rumoured to be considering buying Boston Scientific. Because of the high rumoured price, Boston Scientific is up today, and Stryker is down. He thinks that this area is very investible because long-term growth is so good. People should have an investment in this area. The 10% drop in the stock price yesterday piqued his interest, at this price. Price at time of interview was $164.15.

biotechnology/pharmaceutical
David Baskin

President, Baskin Wealth Manage...

Price Price
$162.540
Owned Owned
No

TOP PICK
Stryker Corp.(SYK-N) 

March 21, 2018

Orthopedic equipment is a key part of their business. The frontrunner and pioneer of robotics in surgery, and gaining market share. For medtech, Stryker is where to be. (Analysts' target of $173.67)

biotechnology/pharmaceutical

Orthopedic equipment is a key part of their business. The frontrunner and pioneer of robotics in surgery, and gaining market share. For medtech, Stryker is where to be. (Analysts' target of $173.67)

biotechnology/pharmaceutical
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$164.730
Owned Owned
Yes

BUY
Stryker Corp.(SYK-N) 

March 21, 2018

Smith & Nephew or Stryker? Smith: Knows it only marginally. The options S&N were generation aren't attractive enough for him to buy. Stryker: Keep an eye on this. Their robotic surgery is cutting a strong profile in orthopedic surgeries. It's definitely becoming the market leader.

biotechnology/pharmaceutical

Smith & Nephew or Stryker? Smith: Knows it only marginally. The options S&N were generation aren't attractive enough for him to buy. Stryker: Keep an eye on this. Their robotic surgery is cutting a strong profile in orthopedic surgeries. It's definitely becoming the market leader.

biotechnology/pharmaceutical
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$164.730
Owned Owned
Yes

PAST TOP PICK
Stryker Corp.(SYK-N) 

February 14, 2018

(A Top Pick Mar. 16/17, Up 20%) Like the healthcare equipment space. Aging demographics are positive. They're getting into robots in surgeries, which he views as positive. Expects it to grow in this area.

biotechnology/pharmaceutical

(A Top Pick Mar. 16/17, Up 20%) Like the healthcare equipment space. Aging demographics are positive. They're getting into robots in surgeries, which he views as positive. Expects it to grow in this area.

biotechnology/pharmaceutical
Zachary Curry

Chief Oper, Davis-Rea Ltd....

Price Price
$156.240
Owned Owned
Yes

HOLD
Stryker Corp.(SYK-N) 

February 12, 2018

Looks okay. Hold it. Worry about it around $140 on the downside. Likes to see a stock fall and then hold, because it shows a dedicated base of shareholders and not a herd mentality. Makes him more confident.

biotechnology/pharmaceutical

Looks okay. Hold it. Worry about it around $140 on the downside. Likes to see a stock fall and then hold, because it shows a dedicated base of shareholders and not a herd mentality. Makes him more confident.

biotechnology/pharmaceutical
Elliott Fishman

Director o, Trading Services Gro...

Price Price
$153.660
Owned Owned
Unknown

WEAK BUY
Stryker Corp.(SYK-N) 

December 7, 2017

It is not as diversified as JNJ-N.  He prefers ETFs to capture the theme because you don’t get the risk.

biotechnology/pharmaceutical

It is not as diversified as JNJ-N.  He prefers ETFs to capture the theme because you don’t get the risk.

biotechnology/pharmaceutical
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$151.150
Owned Owned
Unknown

BUY on WEAKNESS
Stryker Corp.(SYK-N) 

October 17, 2017

He likes this company. Anything in the S&P 500, or even the S&P 100, is perfect for him. This closed at $147.29. Has a model price of $140, and the stock is just a little ahead of itself. Would be a buyer on any pullback.

biotechnology/pharmaceutical

He likes this company. Anything in the S&P 500, or even the S&P 100, is perfect for him. This closed at $147.29. Has a model price of $140, and the stock is just a little ahead of itself. Would be a buyer on any pullback.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Exec, Acker Finley Inc....

Price Price
$148.790
Owned Owned
Unknown

HOLD
Stryker Corp.(SYK-N) 

October 13, 2017

Great company. They are improving their return on capital. Have done everything you could possibly want them to do as a company. However, there is a runaway stock price. If you own it, Hold and look for a better exit.

biotechnology/pharmaceutical

Great company. They are improving their return on capital. Have done everything you could possibly want them to do as a company. However, there is a runaway stock price. If you own it, Hold and look for a better exit.

biotechnology/pharmaceutical
Matt Kacur

President, FSA Financial Scienc...

Price Price
$146.690
Owned Owned
Unknown

BUY
Stryker Corp.(SYK-N) 

September 14, 2017

Hips, Knees and Ankles.  They are capturing market share.  He is seeing great take up here.

biotechnology/pharmaceutical

Hips, Knees and Ankles.  They are capturing market share.  He is seeing great take up here.

biotechnology/pharmaceutical
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$144.490
Owned Owned
Yes

Showing 1 to 15 of 56 entries

No Comments.


You must be logged in to comment.

Successfully Saved Company
Successfully Saved Company